CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophages.
Good CARMA: Turning bad tumor-resident myeloid cells good with chimeric antigen receptor macrophages.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
在宗教哲学中,业力的概念代表了一个人过去和现在的行为对其未来的影响。巨噬细胞是高度可塑的细胞,在健康和疾病中具有多种作用。在癌症背景下,巨噬细胞是免疫微环境中最丰富的成员之一,它们通常支持肿瘤生长并抑制抗肿瘤免疫。然而,巨噬细胞并非天生就是坏的。巨噬细胞或其直接祖细胞——单核细胞——被诱导迁移至肿瘤微环境(TME),在此过程中它们被极化为促肿瘤表型。迄今为止,为在癌症中获得治疗效益而耗竭或重新极化肿瘤相关巨噬细胞(TAM)的努力令人失望。相比之下,对巨噬细胞进行基因工程改造,随后使其进入TME,可能使这些易受影响的细胞改过自新。在这篇综述中,我们总结并讨论了巨噬细胞基因工程用于癌症治疗的最新进展。
In religious philosophy, the concept of karma represents the effect of one's past and present actions on one's future. Macrophages are highly plastic cells with myriad roles in health and disease. In the setting of cancer, macrophages are among the most plentiful members of the immune microenvironment where they generally support tumor growth and restrain antitumor immunity.
However, macrophages are not necessarily born bad. Macrophages or their immediate progenitors, monocytes, are induced to traffic to the tumor microenvironment (TME) and during this process they are polarized toward a tumor-promoting phenotype. Efforts to deplete or repolarize tumor-associated macrophages (TAM) for therapeutic benefit in cancer have to date disappointed.
By contrast, genetic engineering of macrophages followed by their transit into the TME may allow these impressionable cells to mend their ways. In this review, we summarize and discuss recent advances in the genetic engineering of macrophages for the treatment of cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。